Details for Patent: 8,445,524

Which drugs does patent 8,445,524 protect, and when does it expire?

Patent 8,445,524 protects TREANDA and is included in one NDA.

Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventeen patent family members in eleven countries.

Summary for Patent: 8,445,524

Title:	Solid forms of bendamustine hydrochloride
Abstract:	Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
Inventor(s):	Courvoisier; Laurent D. (Thorndale, PA), McKean; Robert E. (Chester Springs, PA), Jansch; Hans-Joachim (Radebeul, DE)
Assignee:	Cephalon, Inc. (Frazer, PA)
Application Number:	13/301,979
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,445,524
Patent Claim Types: see list of patent claims	Compound; Composition; Use; Formulation; Process;

Drugs Protected by US Patent 8,445,524

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-001	Mar 20, 2008	AP	RX	Yes	Yes					Y
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	022249-003	Sep 13, 2013		DISCN	Yes	No					Y
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	022249-004	Sep 13, 2013		DISCN	Yes	No					Y

International Family Members for US Patent 8,445,524

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072777
Canada	2718939
Chile	2009000742
China	101980698
China	103550159